MX2023000692A - Cristal de compuesto de pirimidina. - Google Patents

Cristal de compuesto de pirimidina.

Info

Publication number
MX2023000692A
MX2023000692A MX2023000692A MX2023000692A MX2023000692A MX 2023000692 A MX2023000692 A MX 2023000692A MX 2023000692 A MX2023000692 A MX 2023000692A MX 2023000692 A MX2023000692 A MX 2023000692A MX 2023000692 A MX2023000692 A MX 2023000692A
Authority
MX
Mexico
Prior art keywords
crystal
compound
powder
ray diffraction
characteristic peak
Prior art date
Application number
MX2023000692A
Other languages
English (en)
Spanish (es)
Inventor
Hiroyoshi Yamanaka
Takahiro Asai
Hiroyuki Nakamura
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2023000692A publication Critical patent/MX2023000692A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Liquid Crystal Substances (AREA)
MX2023000692A 2020-07-15 2021-07-14 Cristal de compuesto de pirimidina. MX2023000692A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020121520 2020-07-15
PCT/JP2021/026460 WO2022014638A1 (ja) 2020-07-15 2021-07-14 ピリミジン化合物の結晶

Publications (1)

Publication Number Publication Date
MX2023000692A true MX2023000692A (es) 2023-02-13

Family

ID=79554693

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000692A MX2023000692A (es) 2020-07-15 2021-07-14 Cristal de compuesto de pirimidina.

Country Status (12)

Country Link
US (1) US12492208B2 (cg-RX-API-DMAC7.html)
EP (1) EP4183788A4 (cg-RX-API-DMAC7.html)
JP (1) JP7391226B2 (cg-RX-API-DMAC7.html)
KR (1) KR102914926B1 (cg-RX-API-DMAC7.html)
CN (1) CN116249534B (cg-RX-API-DMAC7.html)
AU (1) AU2021307245B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023000765A2 (cg-RX-API-DMAC7.html)
MX (1) MX2023000692A (cg-RX-API-DMAC7.html)
MY (1) MY207540A (cg-RX-API-DMAC7.html)
PH (1) PH12023550116A1 (cg-RX-API-DMAC7.html)
TW (1) TWI905228B (cg-RX-API-DMAC7.html)
WO (1) WO2022014638A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022282261A1 (en) * 2021-05-24 2023-12-21 Taiho Pharmaceutical Co., Ltd. Treatment methods for subjects with cancer having an aberration in egfr and/or her2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
TW201336847A (zh) * 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
TWI605049B (zh) * 2015-01-30 2017-11-11 Taiho Pharmaceutical Co Ltd Novel salts of condensed pyrimidine compounds and their crystallization
SG11201708793SA (en) * 2015-05-12 2017-11-29 Taiho Pharmaceutical Co Ltd Crystals of azabicyclic compound
KR102075886B1 (ko) 2015-09-01 2020-02-11 다이호야쿠힌고교 가부시키가이샤 신규한 피라졸로[3,4-d]피리미딘 화합물 또는 그 염
JP7223684B2 (ja) * 2017-02-28 2023-02-16 大鵬薬品工業株式会社 ピラゾロ[3,4-d]ピリミジン化合物を用いた抗腫瘍効果増強剤
WO2020004546A1 (ja) 2018-06-28 2020-01-02 日本電気株式会社 遠隔制御装置、遠隔制御方法及びプログラム
TWI769395B (zh) 2018-08-29 2022-07-01 日商大鵬藥品工業股份有限公司 以吡唑并[3,4-d]嘧啶化合物為有效成分之治療劑
PL3909584T3 (pl) 2019-01-11 2024-03-25 Taiho Pharmaceutical Co., Ltd. Związek pirymidynowy lub jego sól
JP7164455B2 (ja) 2019-01-31 2022-11-01 理想科学工業株式会社 容器
TW202216151A (zh) * 2020-07-15 2022-05-01 日商大鵬藥品工業股份有限公司 含有使用於腫瘤之治療之嘧啶化合物之組合
KR102873219B1 (ko) * 2020-07-15 2025-10-17 다이호야쿠힌고교 가부시키가이샤 Egfr 저해제

Also Published As

Publication number Publication date
PH12023550116A1 (en) 2024-06-24
KR20230034341A (ko) 2023-03-09
CA3189457A1 (en) 2022-01-20
TWI905228B (zh) 2025-11-21
AU2021307245A1 (en) 2023-03-02
JP7391226B2 (ja) 2023-12-04
US20230331730A1 (en) 2023-10-19
MY207540A (en) 2025-03-04
AU2021307245B2 (en) 2024-02-29
TW202216717A (zh) 2022-05-01
EP4183788A4 (en) 2024-07-17
US12492208B2 (en) 2025-12-09
WO2022014638A1 (ja) 2022-01-20
CN116249534B (zh) 2025-03-25
CN116249534A (zh) 2023-06-09
EP4183788A1 (en) 2023-05-24
KR102914926B1 (ko) 2026-01-19
JPWO2022014638A1 (cg-RX-API-DMAC7.html) 2022-01-20
BR112023000765A2 (pt) 2023-02-07

Similar Documents

Publication Publication Date Title
ZA202309566B (en) 3,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitors
PH12019500930A1 (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
CA2397450A1 (en) Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
EP4653050A3 (en) Cyclobutyl dihydroquinoline sulfonamide compounds
MX2022007842A (es) Derivados biciclicos sustituidos de piperidina utiles como activadores de celulas t.
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
NZ604345A (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
PH12018500437A1 (en) Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
NZ591712A (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
AU6715200A (en) Amides as inhibitors for pyruvate dehydrogenase
MY208150A (en) Salts, crystal forms, and production methods thereof
MX2020008110A (es) Sal de compuesto de pirazolo[1,5-a]pirimidina y cristales de la misma.
EP4403174A3 (en) Pyrrolo[1,2-b]pyridazine derivatives
MX357874B (es) Procesos para preparar inhibidores de proteinas janus cinasas (jak) y compuestos intermediarios relacionados.
PH12021552533A1 (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
ZA202106014B (en) Solid forms of condensed pyrazines as syk inhibitors
WO2025014877A3 (en) Triazolo wrn inhibitors
PH12023550116A1 (en) Crystal of pyrimidine compound
WO2023129513A3 (en) Bicyclic heteroaromatic inhibitors of nicotinamide n-methyltransferase, and compositions and uses thereof
PH12021551957A1 (en) 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
WO2020016302A8 (en) A xinafoate salt of a jak inhibiting compound
NZ742695A (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
WO2023204303A8 (ja) 7H-ピロロ[2,3-d]ピリミジン-4-アミン誘導体の結晶
MX2025001201A (es) Sales y cristales novedosos